Expertise in
51
conditions

Dr. Andrew W. Pippas

Hematology
Regional Oncology LLC
1831 5th Ave, 
Columbus, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
51
conditions
Regional Oncology LLC
1831 5th Ave, 
Columbus, GA 

Overview

Andrew Pippas is a Hematologist practicing medicine in Columbus, Georgia.

Dr. Pippas is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Primary Lymphoma of the Brain, Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 44 clinical trials. Dr. Pippas is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in GA

Hospital Affiliations

St Francis Hospital- Emory Healthcare
Piedmont Newnan Hospital, Inc
Piedmont Columbus Regional Midtown
Piedmont Fayette Hospital
Piedmont Columbus Regional Northside

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Regional Oncology LLC
1831 5th Ave, Columbus, GA 31904
Other Locations
Columbus Ambulatory Healthcare Services Inc.
1800 10th Ave, Columbus, GA 31901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

44 Clinical Trials

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Journal: JCO oncology practice
Published: April 28, 2026
Similar Doctors
Expertise in
51
conditions
Expertise in
51
conditions
Referral may be required

Piedmont Columbus Regional Midtown

710 Center St, 
Columbus, GA 
 (0.2 miles away)
706-320-8780
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Jiang is a Hematologist practicing medicine in Columbus, Georgia. Dr. Jiang is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Idiopathic Neutropenia, Thrombocytopenia, Agranulocytosis, Bone Marrow Aspiration, and Gastrostomy. Dr. Jiang is currently accepting new patients.

Expertise in
39
conditions
Dr. Mohammad J. Ranginwala
Hematology | Oncology
Expertise in
39
conditions
Dr. Mohammad J. Ranginwala
Hematology | Oncology
Referral may be required

Regional Oncology LLC

1831 5th Ave, 
Columbus, GA 
 (0.1 miles away)
706-320-8780
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Ranginwala is a Hematologist and an Oncologist practicing medicine in Columbus, Georgia. Dr. Ranginwala is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Ranginwala is currently accepting new patients.

Expertise in
30
conditions
Dr. Mukesh Kumar
Hematology
Expertise in
30
conditions
Dr. Mukesh Kumar
Hematology
Referral may be required

Regional Oncology LLC

1831 5th Ave, 
Columbus, GA 
 (0.1 miles away)
706-320-8780
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Mukesh Kumar is a Hematologist practicing medicine in Columbus, Georgia. Dr. Kumar is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, ALK-Positive Non-Small Cell Lung Cancer, Anemia, Bone Marrow Aspiration, and Endoscopy. Dr. Kumar is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew W. Pippas

How do I make an appointment with Dr. Andrew W. Pippas?

You can book an appointment with Dr. Andrew W. Pippas by calling their office at 706-321-6600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew W. Pippas a top-rated expert for Philadelphia-Negative Chronic Myeloid Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew W. Pippas is classified as an Distinguished expert for Philadelphia-Negative Chronic Myeloid Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew W. Pippas specialize in?

While Dr. Andrew W. Pippas is a Hematology, they have specific expertise in Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), and Primary Lymphoma of the Brain. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Andrew W. Pippas participate in research or clinical trials?

Yes. Dr. Andrew W. Pippas has published 9 articles and abstracts on conditions like Philadelphia-Negative Chronic Myeloid Leukemia. You can view a list of Dr. Andrew W. Pippas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew W. Pippas accept my insurance?

Dr. Andrew W. Pippas accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 706-321-6600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pippas's expertise for a condition
ConditionClose
    View All 45 Advanced Conditions
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile